Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGL-001 in advanced solid tumors
NCT06622486Phase 2Recruiting
- Sponsor
- Egle Therapeutics
- Start
- Sep 2024
- Primary completion
- Jan 2027
- Modality
- Immunomodulatory ADCs, Fc Fusion Proteins
- Countries
- 2
01
Overview
Phase 2, open-label trial of EGL-001 in solid tumor, sponsored by Egle Therapeutics. Primary endpoints: Dose-Limiting Toxicities and Maximum Tolerated Dose. Started Sep 2024; status: recruiting.
02
Drugs
EGL-001
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06622486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06622486.